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EDITORIAL
GB virus-C (hepatitis G virus) nostalgia
The newly discovered human flavivirus identified as GB virus-C
[1] and hepatitis G virus (HGV) [2], presents intriguing challenges
in virology, epidemiology, and blood banking. Its clinical rele-
vance for hepatology, however, appears to have been short-lived.
Murthy and colleagues in this issue of Kidney International [3]
provide additional evidence that the virus is not associated with
clinically significant acute or chronic hepatitis. Utilizing an exten-
sive serum bank and clinical database developed for ongoing
studies of hepatitis C virus (HCV) in the setting of chronic renal
disease, the authors screened 465 patient sera for the presence of
GBV-C RNA. In doing so, they identified one of the larger
cohorts of GBV-C infected individuals described to date (N 5
146), lending strength to their conclusions. GBV-C infection was
observed in 29% of patients with end-stage renal disease awaiting
renal transplantation, at similar frequencies among those with and
without antibody to HCV (35 vs. 29%, respectively). There were
no significant differences in history of liver disease, chronic
hepatitis, or of elevated ALT between patients with and without
GBV-C infection. The authors conclude that GBV-C is not
associated with acute or chronic hepatitis, and review the prepon-
derance of evidence that has accumulated over the past few years
supporting this position. They certainly are not alone in this
viewpoint. In two compelling studies, Alter and colleagues found
no association of HGV with community acquired acute hepatitis
or post-transfusion hepatitis [4, 5]. Theodore and Lemon were so
impressed with the notion of ‘hepatitis virus’ as misnomer that
they proposed as an alternative, ‘human orphan flavivirus’ [6];
Pessoa and Wright characterized it as ‘a virus in search of a
disease’ [7], and Miyakawa and Mayumi, ‘an accidental tourist’
[8].
As the description ‘orphan flavivirus’ suggests, we simply do not
know enough, yet, about the epidemiology and pathogenesis of
GBV-C to determine its ultimate clinical significance for humans.
There is no question though that it has found a family among the
blood-borne viruses that can be transmitted through transfusion
[5], intravenous drug abuse [9], and organ transplantation. How-
ever, in studies published to date, the clinical significance of such
transmission was minimal in the majority, and in those few cases
where significant disease was observed, other, unidentified agents
may also have been transmitted. As previously alluded [5], this
orphan may run, on occasion, with hoodlums. Alternatively, such
observations may reflect uncommon outcomes of what are typi-
cally clinically silent infections. As with its distant cousin HCV,
persistent infection is readily established, but in striking contrast,
host development of an antibody response to the GBV-C enve-
lope protein appears to ‘clear’ infection [10]. This observation
leads to several considerations. First, to estimate the true preva-
lence of GBV-C exposure in a population, assays for both RNA
and antibody must be performed. In doing so, Guiterrez et al
found evidence of GBV-C exposure in 5.5% of volunteer blood
donors, 90% of intravenous drug users, and 42 and 43% of
patients with chronic and acute nonA-E hepatitis, respectively
[10]. Thus, virus infection is even more prevalent than previously
suspected, and this suggests that mechanisms of transmission
other than blood exposure are also significant. Second, the clinical
events occurring simultaneously with seroconversion and clear-
ance of infection are not well characterized. For instance, tran-
sient ALT elevation may occur in that setting. Thus, it would be
interesting to know for the present and other recent cohort
studies, if the addition of anti-E2 antibody screening would alter
current conclusions regarding GBV-C and liver disease. The
answer will probably once again be ‘no association,’ but until then,
the question flickers for another day. Meanwhile, efforts to fully
characterize the clinical significance of this virus and its epidemi-
ology will continue.
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